EP300 and schizophrenia: Although metabolic alterations have been described in schizophrenia patients even in the absence of AP treatment, we found no association between the genetically predicted EP300 expression levels and the metabolic status of FEP patients at baseline, suggesting that this gene might be related to the AP effects instead of being a risk factor for the metabolic dysregulation associated with the disease.